Bisphosphonates and Osteonecrosis symposium (SW16-02-02-1)

AvailabilityCourse has taken place
Documents
Programme

Need help viewing PDF documents?

SubjectOral and maxillofacial surgery
DescriptionA two part lecture: Part 1 - Bone modulating agents and prevention of MRONJ. Diagnosis and Management of MRONJ Part 2 - Current Concepts on Bisphosphonates, bone modulating agents, osteonecrosis and dentistry
Additional information

This meeting is run jointly between the Bristol BDA and Dept of Postgraduate Dental Education - Health Education South West

REGISTRATION IS FROM 6PM, WITH THE ACTUAL LECTURE STARTING AT 6.30PM.

VenueFuture Inn Hotel, Bristol - Bristol & N Somerset  View details
Date & timeTuesday 2 February 2016, 18:00 to 22:00
LecturersMs Sarah Taylor & Dr Talli Taylor  View details
Target audience

Recommended to all

Development outcomeNo development outcome
Course styleLecture
Catering Meal
Core topic Not a core topic
CPD hours2:30
Cost£35.00
Aims

To update delegates on bisphosphonates, new anti-resorptive bone agents and anti-angiogenic medications, their mechanisms of action and indication for prescription

Objectives
  • To be aware of the clinical presentation, signs and symptoms of a medication related osteonecrosis of the jaw (MRONJ)
  • To be aware of diagnosis and management of patients with an MRONJ and when to refer
  • To be aware of assessing patient risk of an MRONJ and alternative treatment strategies in the prevention of MRONJ
  • To be able to manage patients on bisphosphonates and other bone anti-resorptive medications
  • to be able to ascertain when to refer patients for surgical treatment and when treatment is appropriate in primary dental care
  • To be able to diagnose and osteonecrosis and prepare the patient for anticipated management upon referral
  • To be able to prevent any procedures with may induce an osteonecrosis

LEARNING OUTCOME

For delegates to know what the risks for medication-related osteonecrosis of the jaw (MRONJ) are, how to manage the risks, and when to refer to secondary care.  Delegates will also gain an understanding of the secondary care management of these patients.